AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05257161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mo.Ma™
Description: Embolic Protection System for Carotid Artery Revascularization ( proximal - occlusion) + stent CGuardTM™
Study NCT05257980 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement (ONS)
Description: At baseline, the investigating dietitian/nurse will record several measures, including clinical history and symptoms over the previous 24 hours. In addition, patients who are already receiving an ONS will continue their prescribed ONS for 1 day in which their gastrointestinal tolerance, ONS compliance and acceptability will be recorded. All patients will then receive standardised dietary advice in addition to one of the four trial ONS products daily for 28 days. The type of ONS will be agreed with the patient and the investigating dietitian/nurse, and the ONS prescription will be determined on an individual basis by the investigating dietitian/nurse responsible for the patient's nutritional management (1-3 ONS per day; aligned with guidelines set out within the Malnutrition Pathway). The type of ONS prescribed will be the same throughout the 28 days and will be taken orally.
Study NCT05597891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hēlo PE Thombectomy System
Description: Treatment with the Hēlo PE Thombectomy System for thromboembolectomy
Study NCT05472220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given orally
Study NCT05472220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV during imaging
Study NCT05472220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon-13 (13C) Pyruvate
Description: Given IV
Study NCT05472220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: Self-applied devices that sit partially beneath the skin
Study NCT04493034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: The art therapist will assist each participant in producing a bound collection of participant art works/writings for personal, group and/or caregiver inspiration, at the participant's request. For in-person sessions, a variety of studio-based art and writing materials will be available for participant selection and creation. Each session will be directed in the following manner:~* New therapeutic prompt or bridge from prior session~* Creative expression, opportunity for reflection, verbal sharing / processing, and a session summary~* Discussion of action plan for the next consecutive, at-home session (weekly assignment).~Possible wellness themes for each session (in-person or at-home) may include: mental health, physical health, emotional health, spiritual health, relational health (family and social), or occupational health/financial health.
Study NCT04493034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Participants have the opportunity to engage in: learning an instrument, active music-making, receptive music-listening, singing, improvisation, song-writing, education on music technology, or music discussion. During in-person musical sessions the six psychosocial goals promoted by the music therapist include: 1) self-care/self-love, 2) support systems, 3) practicing positivity 4) gratitude 5) mindfulness/living in the moment, and 6) goal-setting.~For at-home assignments, participants will be asked to pick a song of the week that coincides with the theme/goal discussed in previous session(s). They will be asked to write a journal entry about the topic discussed. Journal entries can be freely written or a prompt/question can be provided. If participants do not have access to search for songs or listen to music as at home, they may select a piece from the session and be given lyrics and/or a recording on an .mp3 player returned at conclusion of study.
Study NCT06457438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Elecsys Anti-HEV IgG, IgM
Description: Diagnostic test used to determine antibodies in blood and serum.
Study NCT06320067 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiotherapy (SABR)
Description: SABR is a way of giving focused high-dose radiotherapy. SABR given with a dose fractionation schedule of 30Gy in 3-5 fractions over 1-2 weeks to up to 5 metastatic lesions in the bone and/or non-regional (extra-pelvic) lymph nodes.
Study NCT04618705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation
Description: Participants will start a smoking cessation program.
Study NCT05078034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helmet Non-Invasive Ventilation (HNIV)
Description: HNIV will be connected to a ventilator by a conventional closed respiratory circuit. Sessions of HNIV will be delivered with PEEP targeting a minimum 12 hours/day. PEEP will be titrated according to patient comfort, work of breathing, and O2 saturation. Pressure support will be titrated to lowest level tolerated. Between HNIV sessions, patients will be supported with HFNO at the same required FiO2. Starting on study day 3, patients will be screened for discontinuation of HNIV. Once HNIV is stopped, patients will be transitioned to HFNO and then weaned from HFNO as tolerated.
Study NCT05078034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Oxygen
Description: HFNO will be provided. FiO2 will be titrated to achieve a target O2 saturation of 92-97%, and flows will be initiated at 50 litres/minute and titrated as per usual practice for comfort and oxygenation. Once the target O2 saturation is achieved, the FiO2 will be titrated to the minimal value to maintain this target saturation. HFNO will be provided continuously over a minimum of 2 calendar days. Starting on study day 3, patients will be weaned from HFNO as tolerated.
Study NCT05475873 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: normal saline
Description: A bolus of normal saline (2 ml) by IV was given 5 min before spinal anesthesia.
Study NCT05475873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Description: A bolus of ondansetron (2 ml; 4mg) by IV was given 5 min before spinal anesthesia.
Study NCT05475873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Description: A bolus of ondansetron (2 ml; 8mg) by IV was given 5 min before spinal anesthesia.
Study NCT06320067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: 177Lu-PSMA-617 is a nuclear medicine therapy. Patients will receive 177Lu-PSMA-617 to a dose of 7.4GBq. Each cycle will consist of 2 doses, 1 week apart (on day 1 and day 8) and will last 6 weeks. Treatment will be given for up to 3 cycles (6 doses).
Study NCT06320067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib and Abiraterone Acetate Dual Action Tablet DAT
Description: Combination product containing Niraparib (PARP inhibitor) and Abiraterone Acetate (ARSI). The regular-strength dual-action tablet (DAT) contains 100 mg niraparib/500mg AA per tablet. Patients take 2 tablets a day and receive a of total dose 200 mg niraparib/1000 mg AA. A low-strength DAT tablet containing 50 mg niraparib/500 mg AA may be available for participants requiring a dose reduction of niraparib.
Study NCT06320067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone Acetate is an ARSI. Single agent Abiraterone Acetate may be used in patients randomised to receive Niraparib and Abiraterone Acetate.
Study NCT06320067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: Apalutamide is an ARSI administered as a 240mg oral dose (four tablets taken together at the same time every day) with or without food. It is given daily in 28-day cycles.
Study NCT06320067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen Deprivation Therapy (ADT)
Description: Long-term, continuous treatment with ADT (bilateral orchidectomy, LHRH agonists or LHRH antagonists) if not previously surgically castrated. The choice of ADT is at the discretion of the investigator. This will be given as standard of care as per local guidelines.
Study NCT06320067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Description: Long-term, continuous treatment with ADT (bilateral orchidectomy, LHRH agonists or LHRH antagonists) if not previously surgically castrated. The choice of ADT is at the discretion of the investigator. This will be given as standard of care as per local guidelines.
Study NCT06320067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen Receptor Signalling Inhibitor (ARSI)
Description: Second generation ARSI (Abiraterone Acetate and Prednisolone \[AA+P\], Enzalutamide, Apalutamide or Darolutamide). This will be given as standard of care as per local guidelines.~Abiraterone acetate will be administered as a single 1000mg once daily dose (4 tablets to be taken together once a day) with prednisolone 5mg once daily to prevent secondary mineralocorticoid excess.~Enzalutamide will be administered as a 160mg oral dose (four capsules taken together at the same time every day) with or without food. Enzalutamide is administered daily in 28-day cycles.~Apalutamide will be administered as 240mg oral dose (four tablets taken together at the same time every day) with or without food. Apalutamide is administered daily in 28-day cycles. Patients require thyroid function monitoring.~Darolutamide will be administered as 600mg oral dose (two 300mg tablets taken together) with or without food. Darolutamide is administered twice daily in 28-day cycles.
Study NCT06320067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Receptor Signalling Inhibitor (ARSI)
Description: Second generation ARSI (Abiraterone Acetate and Prednisolone \[AA+P\], Enzalutamide, Apalutamide or Darolutamide). This will be given as standard of care as per local guidelines.~Abiraterone acetate will be administered as a single 1000mg once daily dose (4 tablets to be taken together once a day) with prednisolone 5mg once daily to prevent secondary mineralocorticoid excess.~Enzalutamide will be administered as a 160mg oral dose (four capsules taken together at the same time every day) with or without food. Enzalutamide is administered daily in 28-day cycles.~Apalutamide will be administered as 240mg oral dose (four tablets taken together at the same time every day) with or without food. Apalutamide is administered daily in 28-day cycles. Patients require thyroid function monitoring.~Darolutamide will be administered as 600mg oral dose (two 300mg tablets taken together) with or without food. Darolutamide is administered twice daily in 28-day cycles.
Study NCT06320067 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Local Radiotherapy
Description: Either 36.25Gy given in 5 fractions over 1-2 weeks to prostate or 60Gy in 20 fractions over 4 weeks to prostate (± 47Gy in 20 fractions to pelvic lymph nodes ± 51Gy in 20 fractions boost to involved nodes).
Study NCT06320067 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local Radiotherapy
Description: Either 36.25Gy given in 5 fractions over 1-2 weeks to prostate or 60Gy in 20 fractions over 4 weeks to prostate (± 47Gy in 20 fractions to pelvic lymph nodes ± 51Gy in 20 fractions boost to involved nodes).
Study NCT06320067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone should also be administered 5mg daily using local pharmacy prescribing.
Study NCT06320067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Maximum of 6 cycles every 3 weeks may be given at a dose of 75mg/m2 by IV infusion.
Study NCT06320067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Maximum of 6 cycles every 3 weeks may be given at a dose of 75mg/m2 by IV infusion.
Study NCT04884308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG TICE Vaccine
Description: Intradermal vaccination with BCG TICE
Study NCT04884308 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG TICE Vaccine
Description: Intradermal vaccination with BCG TICE
Study NCT05573737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: education about ubilical cord care
Study NCT05905640 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Method of PrEP delivery and consultation
Description: All core PrEP services that include HIV testing, risk assessment, clinical review PrEP initiation, prescription, dispensing, and follow-up will be performed in a one-stop consultation with a single provider.
Study NCT05133804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Ritalin 10mg
Study NCT05133804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reboxetine
Description: Reboxetine 4mg
Study NCT05133804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to Reboxetine
Study NCT05133804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to Ritalin
Study NCT05504902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile coordinated reset
Description: The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants with Advanced stage Parkinson's disease
Study NCT06562179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci SP® Single-Port Robotic Surgical System
Description: The da Vinci SP® Surgical System is designed to enable the performance of surgical procedures using a minimally invasive single-port approach. The system consists of a Surgeon Console, a Vision Cart, and a Patient Cart and is used with a camera, instruments, and accessories.
Study NCT05629728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Description: Sun-style Tai Chi (21 forms)
Study NCT06034483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercise training
Description: * Pelvic floor muscle contraction will be verified with vaginal palpation and a progressive pelvic floor muscle training program will be given.~* In the pelvic floor muscle training program:~* Fast and slow pelvic floor muscle contractions will be taught,~* Training will begin with 3 sets of exercises per day, exercise compliance of individuals will be monitored in the controls to be made every 2 weeks, and the number of exercise sets will be increased by one set.~* 1 set of exercises: It will include 10 fast + 10 continuous (frequent-(3-10 sec) hold-release) contractions.~* Individuals will be tracked with exercise diaries.~* At the end of the 8th week, post-intervention evaluations will be made again.~* The exercise program will be completed with a total of 6 sets of exercises per day (60 fast and 60 slow per day).
Study NCT06034483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient/individual education
Description: In the individual/patient information training, training will be given on menopause, sexual health, pelvic floor health and lifestyle. This training will cover more specifically the following topics:~* Explaining menopause and menopausal symptoms~* Defining the Genitourinary Syndrome of Menopause (MGS)~* The effect of MGS on sexual function cycle and sexual function,~* Conservative recommendations on MGS management~* Explaining pelvic floor anatomy and function and recommendations for pelvic floor health.~The training will take approximately 1 hour and the training will be repeated at the end of the 1st month.
Study NCT06034483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient/individual education
Description: In the individual/patient information training, training will be given on menopause, sexual health, pelvic floor health and lifestyle. This training will cover more specifically the following topics:~* Explaining menopause and menopausal symptoms~* Defining the Genitourinary Syndrome of Menopause (MGS)~* The effect of MGS on sexual function cycle and sexual function,~* Conservative recommendations on MGS management~* Explaining pelvic floor anatomy and function and recommendations for pelvic floor health.~The training will take approximately 1 hour and the training will be repeated at the end of the 1st month.
Study NCT05889546 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Lung, liver, skin, subcutaneous metastases, and blood specimens may be collected via rapid autopsy within 10 hours of expiration.
Study NCT05363085 — intervention group
Intervention type: OTHER
Intervention: Mechanically ventilated neurosurgical patients
Description: Observational study where respiratory variables and intracranial pressure will be measured during mechanical ventilation and during specific respiratory manoeuvres. No intervention is planned.
Study NCT06058871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular messages
Description: The EMI-I messages will be delivered in sequence over three months. The content, frequency, and timing of the messages will be determined by participant preferences, as determined during the baseline evaluation, as personalisation is central to such cognitive and behavioural changes. The messages will mainly be text-based, but other forms such as videos will also be used, depending on the needs of the participants.
Study NCT06058871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led real-time support messages (chat type)
Description: The nurse will initiate 10-15-minute chats via an online platform (e.g., WhatsApp) after all instant messages for each session have been delivered. The nurse will guide the participants to set goals for breastfeeding. Any anticipated barriers will be discussed. The participants can also initiate the chats. While there is no limit to the number of chat messages, nurse-led real-time support messages will be provided during working hours (i.e., 9 am-6 pm on weekdays).
Study NCT05459220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0410 Injection
Description: SHR0410 Injection（Low Dose）
Study NCT05459220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0410 Injection
Description: SHR0410 Injection（High Dose）
Study NCT05459220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for SHR0410 Injection.
Study NCT05474443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial gun with conventional therapy
Description: MYofascial gun was applied for the duration of 5 minutes over upper trapezius muscle. every week, on first two sessions frequency was set to 1-2 then for next two 3-4 and so on conventional therapy Hot Pack applied at the beginning of session for 10 minutes Muscle stretching of Upper Trapezius, Levator Scapulae and Pectoralis Major applied with holding time 20 seconds and 4 repetitions.~Cold pack was applied at the end of the session for few minutes
Study NCT05474443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instrument Assisted Soft Tissue Mobilization with Conventional therapy
Description: Graston's tool was applied over upper trapezius muscle from its origin to insertion kept at the angle of 45 Conventional Therapy Hot pack 10mins Upper Trapezius, Levator scapule and Pectoralis major muscle stretching(20s hold and 4 reps) Cold pack for few minutes
Study NCT04957940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOFlipid
Description: Intravenous fish-oil-based lipid (SMOF lipid 20%) (Fresenius Kabi, Bad Homburg, Germany) emulsion supplementation to standard enteral nutrition in a dose of 100 ml/day at a rate of 12.5 ml/h over 8 h daily for 5 days.
Study NCT05624632 — intervention group
Intervention type: OTHER
Intervention: Remote cognitive testing
Description: Remote cognitive testing
Study NCT05038514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: musıc therapy
Description: After the prone position was given to the patients, according to the randomization table, the intervention group was given 30 minutes by the nurse. nature-based music therapy will be applied.
Study NCT05140980 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: evaluation of women's knowledge concerning sexuality
Study NCT04957940 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Receive standard enteral nutrition plus 100 ml/day 0.9% normal saline at a rate 12.5 ml/h over 8 h for 5 days
Study NCT05914259 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Following the manner of observational study, no intervention will be provided in the study.
Study NCT06070571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yarrow and moringa mixture
Description: yarrow and moringa mixture nano particles loaded on buccal film
Study NCT06070571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yarrow and moringa mixture
Description: yarrow and moringa mixture nano particles loaded on buccal film
Study NCT04149275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Treatment with oral Cabozantinib once daily
Study NCT06350500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Receive patient navigation
Study NCT06350500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Ancillary studies
Study NCT01053065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin - Cholestyramine - Sitosterol
Study NCT05946486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immunomodulatory treatment by rituximab
Description: 1g for adults or 375 mg/m2 for children, renewed at 14 days (+/- 3 days)
Study NCT06454968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib, obinutuzumab, lenalidomide
Description: Orelabrutinib: 150mg qd d1-d21/C1-C6 obinutuzumab: 1000mg iv d1,d8,d15/c1, 1000mg iv d1/C2-C6 lenalidomide：25mg po qd d1-14/C1-C6 Orelabrutinib: 150mg qd d1-d28/C7-C12
Study NCT04149275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV administration of Ipilimumab on 21 day cycles